邁威生物(688062.SH):地舒單抗長期治療可持續提升各部位骨密度,無平台期
格隆匯8月8日丨邁威生物(688062.SH)近期在接待機構投資者調研時表示,地舒單抗長期治療可持續提升各部位骨密度,無平台期。與雙膦酸鹽藥物的作用機制不同,地舒單抗不會在骨質基質中沉積,其抑制骨轉換作用具有可逆性,停藥後BMD在1-2年內回落至治療前水平,骨質風險回升,因此地舒單抗可以長期使用。(摘自2021年《地舒單抗在骨質疏鬆症中臨牀合理用藥中國專家建議》)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.